I
Ilse K. Luirink
Researcher at University of Amsterdam
Publications - 17
Citations - 622
Ilse K. Luirink is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Familial hypercholesterolemia & Evolocumab. The author has an hindex of 8, co-authored 13 publications receiving 306 citations.
Papers
More filters
Journal ArticleDOI
20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
Ilse K. Luirink,Albert Wiegman,D Meeike Kusters,Michel H. Hof,Jaap W. Groothoff,Eric de Groot,John J.P. Kastelein,Barbara A. Hutten +7 more
TL;DR: In this study, initiation of statin therapy during childhood in patients with familial hypercholesterolemia slowed the progression of carotid intima-media thickness and reduced the risk of cardiovascular disease in adulthood.
Journal ArticleDOI
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
Raul D. Santos,Andrea Ruzza,G. Kees Hovingh,Albert Wiegman,François Mach,Christopher E. Kurtz,Andrew Hamer,Ian Bridges,Andrea Bartuli,Jean Bergeron,Jean Bergeron,Tamas Szamosi,Saikat Santra,Claudia Stefanutti,Olivier S. Descamps,Susanne Greber-Platzer,Ilse K. Luirink,John J.P. Kastelein,Daniel Gaudet +18 more
TL;DR: In this trial involving pediatric patients with familial hypercholesterolemia, evolocumab reduced the LDL cholesterol level and other lipid variables and results for all secondary lipid variables were significantly better with evolOCumab than with placebo.
Journal ArticleDOI
Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations
Evan A. Stein,Eldad J. Dann,Albert Wiegman,Flemming Skovby,Daniel Gaudet,Etienne Sokal,Min-Ji Charng,Mafauzy Mohamed,Ilse K. Luirink,Joel S. Raichlen,Mattias Sundén,Stefan Carlsson,Frederick J. Raal,John J.P. Kastelein +13 more
TL;DR: This first-ever pediatric HoFH statin trial demonstrated safe and effective LDL-C reduction with rosuvastatin 20 mg alone or added to ezetimibe and/or apheresis, and was maintained for 12 weeks.
Journal ArticleDOI
Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review.
Ilse K. Luirink,Jim Determeijer,Barbara A. Hutten,Albert Wiegman,Eric Bruckert,Claus Peter Schmitt,Jaap W. Groothoff +6 more
TL;DR: LA seems to be a safe therapy and substantially reduces LDL-C and xanthomata in children with HoFH and the efficacy with respect to CVD protection as compared with only pharmacologic and dietary treatment remains unclear.
Journal ArticleDOI
Marked plaque regression in homozygous familial hypercholesterolemia
Laurens F. Reeskamp,Nick S. Nurmohamed,Michiel J. Bom,R. Nils Planken,Roel S. Driessen,Pepijn A. van Diemen,Ilse K. Luirink,Jaap W. Groothoff,Irene M. Kuipers,Paul Knaapen,Erik S.G. Stroes,Albert Wiegman,G. Kees Hovingh +12 more
TL;DR: This study describes two severely affected young HoFH patients in whom profound plaque reduction was observed with CCTA after intensive lipid lowering therapy with statins, ezetimibe, LDL apheresis, and evinacumab, and shows that atherosclerotic plaques possess the ability to regress at young age, even inHoFH patients.